Webinar: Building the Intelligence Engine for Drug Discovery R&D Teams

Ben is a Global Account Director on Patsnap’s Life Sciences team, where he works with some of the most innovative organizations in the industry to help them move faster, protect their IP, and stay ahead of a rapidly evolving competitive landscape. With a PhD in biomedical materials, he brings a rare combination of scientific depth and real-world R&D workflow experience to every conversation.

Mark is Patsnap’s Head of Product for Life Sciences, with 20+ years of experience in AI-enabled drug discovery. He spent nine years at BenevolentAI as SVP of Informatics and Data, led the development of ChEMBL and SureChEMBL, and co-founded Kiin Bio to build an AI co-scientist for drug discovery. Across these roles, he developed deep insight into the data challenges facing R&D teams.

James Longden is a cell biologist with a background in early drug discovery and network/systems biology. He spent the first half of his career performing and leading target identification, hit identification and mechanism of action studies at AstraZeneca and Cenix BioScience (a pioneer in RNA interference). He then transitioned into network biology; investigating how we can combine ‘big data’ biology with AI/machine learning for the identification of novel targets and treatment strategies. He has applied these techniques in multiple therapeutic areas as an Associate Professor at the University of Copenhagen, at Pheno Therapeutics, a spin-out developing therapies for neurodegenerative and demyelinating disorders, and at e-therapeutics (a biotech developing siRNA therapeutics). He is currently Senior Director of Life Science at Evolvus, leading the development of new data products for the life sciences industry.